BRIEF-Vivani Medical Receives Regulatory Approval To Initiate First In Human Clinical Trial With Glp-1 Implant In Obese And Overweight Individuals In Australia

Reuters09-26

Sept 26 (Reuters) - Vivani Medical Inc :

* VIVANI MEDICAL RECEIVES REGULATORY APPROVAL TO INITIATE FIRST IN HUMAN CLINICAL TRIAL WITH GLP-1 IMPLANT IN OBESE AND OVERWEIGHT INDIVIDUALS IN AUSTRALIA

* VIVANI MEDICAL INC: TRIAL IS EXPECTED TO BE INITIATED LATER THIS YEAR WITH DATA PROJECTED TO BE AVAILABLE IN 2025

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470273372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-26 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470273372","market":"us","top_or_hot":-1,"title":"BRIEF-Vivani Medical Receives Regulatory Approval To Initiate First In Human Clinical Trial With Glp-1 Implant In Obese And Overweight Individuals In Australia","media":"Reuters","content":"<html><body><p>Sept 26 (Reuters) - Vivani Medical Inc   :</p><p>   * VIVANI MEDICAL RECEIVES REGULATORY APPROVAL TO INITIATE FIRST IN HUMAN CLINICAL TRIAL WITH GLP-1 IMPLANT IN OBESE AND OVERWEIGHT INDIVIDUALS IN AUSTRALIA</p><p>   * VIVANI MEDICAL INC: TRIAL IS EXPECTED TO BE INITIATED LATER THIS YEAR WITH DATA PROJECTED TO BE AVAILABLE IN 2025</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vivani Medical Receives Regulatory Approval To Initiate First In Human Clinical Trial With Glp-1 Implant In Obese And Overweight Individuals In Australia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vivani Medical Receives Regulatory Approval To Initiate First In Human Clinical Trial With Glp-1 Implant In Obese And Overweight Individuals In Australia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-26 20:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 26 (Reuters) - Vivani Medical Inc   :   * VIVANI MEDICAL RECEIVES REGULATORY APPROVAL TO INITIATE FIRST IN HUMAN CLINICAL TRIAL WITH GLP-1 IMPLANT IN OBESE AND OVERWEIGHT INDIVIDUALS IN AUSTRALIA...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VANI","symbol_name":"Vivani Medical, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2470273372","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470273372","pubTimestamp":1727354672,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 26  - Vivani Medical Inc   :   * VIVANI MEDICAL RECEIVES REGULATORY APPROVAL TO INITIATE FIRST IN HUMAN CLINICAL TRIAL WITH GLP-1 IMPLANT IN OBESE AND OVERWEIGHT INDIVIDUALS IN AUSTRALIA   * VIVANI MEDICAL INC: TRIAL IS EXPECTED TO BE INITIATED LATER THIS YEAR WITH DATA PROJECTED TO BE AVAILABLE IN 2025Source text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"VANI":"Vivani Medical, Inc."},"translate_title":"简介-Vivani Medical获得监管部门批准，在澳大利亚肥胖和超重个体中启动首个Glp-1植入物人体临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VANI":0.9},"content_text":"Sept 26 (Reuters) - Vivani Medical Inc   :   * VIVANI MEDICAL RECEIVES REGULATORY APPROVAL TO INITIATE FIRST IN HUMAN CLINICAL TRIAL WITH GLP-1 IMPLANT IN OBESE AND OVERWEIGHT INDIVIDUALS IN AUSTRALIA   * VIVANI MEDICAL INC: TRIAL IS EXPECTED TO BE INITIATED LATER THIS YEAR WITH DATA PROJECTED TO BE AVAILABLE IN 2025Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470273372"}